Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?

Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?

Cardiovascular diseases (CVD) are the leading cause of premature death and disability in humans that are closely related to lipid metabolism and signaling. This study aimed to assess whether circulating lysophospholipids (LPL), lysophosphatidic acids (LPA) and monoacylglycerols (MAG) may be consider...

Full description

Saved in:
Bibliographic Details
Main Authors: Thomas Duflot, Ly Tu, Matthieu Leuillier, Hind Messaoudi, Déborah Groussard, Guillaume Feugray, Saïda Azhar, Raphaël Thuillet, Fabrice Bauer, Marc Humbert, Vincent Richard, Christophe Guignabert, Jérémy Bellien
Format: article
Language:EN
Published: MDPI AG 2021
Subjects:
lysophospholipids
lysophosphatidic acids
cardiovascular diseases
HPLC-MS/MS
rodent models
pulmonary hypertension
Microbiology
QR1-502
Online Access:https://doaj.org/article/2813d9874b6f4b77aef908b7dc9296a5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/2813d9874b6f4b77aef908b7dc9296a5

Similar Items